The estimated Net Worth of John P Mckearn is at least $101 Million dollars as of 26 March 2021. John Mckearn owns over 7,439 units of Allakos Inc stock worth over $732 and over the last 10 years he sold ALLK stock worth over $100,603,191. In addition, he makes $432,260 as Independent Director at Allakos Inc.
Sign up
John McKearn ALLK stock SEC Form 4 insiders trading
John has made over 10 trades of the Allakos Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 7,439 units of ALLK stock worth $855,485 on 26 March 2021.
The largest trade he's ever made was selling 1,150,000 units of Allakos Inc stock on 12 May 2020 worth over $81,696,000. On average, John trades about 110,269 units every 151 days since 2014. As of 26 March 2021 he still owns at least 1,200 units of Allakos Inc stock.
You can see the complete history of John Mckearn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John McKearn biography
Dr. John P. McKearn Ph.D. serves as Independent Director of the Company. Dr. McKearn joined RiverVest Venture Partners, a venture capital firm, in April 2008 as a Venture Partner and has been a Managing Director since April 2011. Prior to joining RiverVest, Dr. McKearn was the Chief Executive Officer of Kalypsys, a biopharmaceutical company, from 2005 to December 2006, its President from 2004 to December 2006 and its Chief Scientific Officer from 2003 to 2005. From 2000 to June 2009, Dr. McKearn served on the board ofIDM Pharma (acquired by Takeda), a biotechnology company. He also previously served on the board of directors of Epimmune, Keel Pharmaceuticals, ZS Pharma, Otonomy and Lumena Pharmaceuticals and currently serves as a member of the board of directors of Arch Oncology, OncoResponse, Good Therapeutics and Adarza Biosystems. From 1987 to 2003, Dr. McKearn worked as a scientist with G.D. Searle & Company, which merged into Pharmacia Corporation in 2000, serving as the head of discovery research from 1997 to 2003. Before that, he was a senior scientist at E.I. DuPont de Nemours and Company, a member of the Basel Institute for Immunology in Basel, Switzerland and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis.
What is the salary of John McKearn?
As the Independent Director of Allakos Inc, the total compensation of John McKearn at Allakos Inc is $432,260. There are 11 executives at Allakos Inc getting paid more, with Robert Alexander having the highest compensation of $12,559,300.
What's John McKearn's mailing address?
John's mailing address filed with the SEC is C/O ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS, CA, 94070.
Insiders trading at Allakos Inc
Over the last 6 years, insiders at Allakos Inc have traded over $246,100,922 worth of Allakos Inc stock and bought 5,181,222 units worth $35,384,176 . The most active insiders traders include Paul Edward Walker, Group, Llc Green Jeremy Red..., and Daniel Janney. On average, Allakos Inc executives and independent directors trade stock every 43 days with the average trade being worth of $114,372. The most recent stock trade was executed by Harlan Baird Radford on 28 June 2024, trading 87,064 units of ALLK stock currently worth $87,935.
What does Allakos Inc do?
allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.
What does Allakos Inc's logo look like?
Complete history of John Mckearn stock trades at Otonomy Inc and Allakos Inc
Allakos Inc executives and stock owners
Allakos Inc executives and other stock owners filed with the SEC include:
-
Robert Alexander,
Chief Executive Officer, Director -
Adam Tomasi,
President, Chief Operating Officer -
Henrik Rasmussen,
Chief Medical Officer -
Leo Redmond,
Chief Financial Officer -
Mark Asbury,
Chief Legal Officer and General Counsel -
Dr. Robert Alexander Ph.D.,
CEO & Director -
Dr. Adam L. Tomasi Ph.D.,
Pres & COO -
Dr. Henrik Sandvad Rasmussen,
Strategic Advisor -
Mark Asbury,
Chief Legal Officer & Gen. Counsel -
Daniel Janney,
Independent Chair of the Board -
Robert Andreatta,
Independent Director -
John McKearn,
Independent Director -
Paul Walker,
Independent Director -
Steven James,
Independent Director -
Dr. Craig Paterson M.D.,
Chief Medical Officer -
Alan Chang,
Director of Medical Affairs & Data Analytics -
Tim Varacek,
Chief Commercial Officer -
Dr. Sally D. Bolmer,
Sr. VP of Regulatory Affairs & Drug Devel. -
Dr. Ruby Casareno Ph.D.,
Sr. VP of Technical Operations -
Baird Radford III,
Chief Financial Officer -
Group, Llc Green Jeremy Red...,
-
Venture Fund Iii, L.P.River...,
-
Partners Viii, L.P.Alta Par...,
-
Neil Murray Hamilton Graham,
-
Amy L Ladd,
-
Dolca Thomas,
-
Partners Next Gen Fund I Ma...,
-
Peter A Hudson,
-
Robert J More,
-
Guy P Nohra,
10% owner -
Natalie C. Holles,
Director -
Partners Next Gen Fund I Ma...,
-
Margaret Nell Fitzgerald,
General Counsel and Secretary -
Craig A. Paterson,
Chief Medical Officer -
Everett Rand Sutherland,
Director -
Partners Management Viii, L...,
-
Chin Hyok Lee,
Chief Medical Officer -
Harlan Baird Radford,
Chief Financial Officer